Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin · 1 trial · 1 indication
Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 6 variables are included in a calculation formula.
| Arm | Type | Description |
|---|---|---|
| Chemotherapy | ACTIVE_COMPARATOR | 3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel |
| Letrozole Palbociclib | EXPERIMENTAL | Drugs: letrozole + palbociclib combination |
| Name | Type | Description |
|---|---|---|
| Fluorouracile | DRUG | - |
| Epirubicin | DRUG | - |
| Cyclophosphamide | DRUG | - |
| Letrozole | DRUG | - |
| Palbociclib | DRUG | - |
Inclusion Criteria: 1. Aged ≥ 18 years, Post-menopausal women 2. Newly diagnosed and operable unilateral invasive breast cancer, not candidate or uncertain for breast conservation - Note: Multicentric/multifocal tumors are allowed provided a maximum of 3 lesions are present, and all share the same ...
Epirubicin is a small molecule oncology drug being studied for use in neoadjuvant operable breast cancer. It is being evaluated in postmenopausal women with stage II-IIIA luminal breast cancer as part of a combination treatment approach. The drug is currently in Phase 2 clinical development.
Epirubicin is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research on the drug for the treatment of neoadjuvant operable breast cancer.
Epirubicin is currently in Phase 2 clinical development for neoadjuvant operable breast cancer. It is an investigational drug and has not yet been approved for this indication. One Phase 2 clinical trial has been completed to evaluate its efficacy and safety.
Epirubicin has been studied in one completed Phase 2 clinical trial, identified as NCT02400567. This trial evaluated the efficacy of a combination treatment including Epirubicin in postmenopausal women with stage II-IIIA luminal breast cancer. The trial enrolled 125 participants and was conducted in France.
Epirubicin is a distinct drug being studied for neoadjuvant operable breast cancer. It is being evaluated in combination with other agents, such as letrozole and palbociclib, in clinical trials. Its specific mechanism of action and molecular targets have not been disclosed in available information.